Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
17 Février 2022 - 1:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing curative therapeutics
leveraging CRISPR-based technologies, today announced that it will
be hosting two virtual investor events in February.
Fourth Quarter and Full-Year 2021 Earnings – February
24, at 8:00 a.m. ETIntellia will present its fourth
quarter and full-year 2021 financial results.
- To join the call, U.S. callers should dial 1-833-316-0545 and
international callers should dial 1-412-317-5726, approximately
five minutes before the call. All participants should ask to be
connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the
call.
NTLA-2001 Interim Clinical Data Update – February 28, at
4:30 p.m. ETIntellia will present additional interim
clinical data from the ongoing Phase 1 study of NTLA-2001 in
patients with transthyretin (ATTR) amyloidosis with polyneuropathy.
The event will include a presentation by Ed Gane, MBChB, MD, FRACP,
MNZM, Professor of Medicine at the University of Auckland, New
Zealand and Chief Hepatologist, Transplant Physician and Deputy
Director of the New Zealand Liver Transplant Unit at Auckland City
Hospital and an investigator in the ongoing NTLA-2001 Phase 1
study, along with members of Intellia’s management team.
- To join the webcast, please visit this link, or the Events and
Presentations page of the Investors & Media section on
Intellia’s website at www.intelliatx.com.
A replay of the events will be available through the Events and
Presentations page of the Investors & Media section on
Intellia’s website at www.intelliatx.com for at least 30 days
following the event.
About NTLA-2001Based on Nobel
Prize-winning CRISPR/Cas9 technology, NTLA-2001 could potentially
be the first single-dose treatment for ATTR amyloidosis. NTLA-2001
is the first investigational CRISPR therapy candidate to be
administered systemically, or through a vein, to edit genes inside
the human body. Intellia’s proprietary non-viral platform deploys
lipid nanoparticles to deliver to the liver a two-part genome
editing system: guide RNA specific to the disease-causing
gene and messenger RNA that encodes the Cas9 enzyme, which
carries out the precision editing. Robust preclinical data, showing
deep and long-lasting transthyretin (TTR) reduction following in
vivo inactivation of the target gene, supports NTLA-2001’s
potential as a single-administration therapeutic. Intellia leads
development and commercialization of NTLA-2001 as part of a
multi-target discovery, development and commercialization
collaboration with Regeneron.
About Intellia TherapeuticsIntellia
Therapeutics, a leading clinical-stage genome editing company, is
developing novel, potentially curative therapeutics leveraging
CRISPR-based technologies. To fully realize the transformative
potential of CRISPR-based technologies, Intellia is pursuing two
primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatx.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Matt CrensonTen Bridge
Communications+1-917-640-7930media@intelliatx.commcrenson@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024